Epidemiology of Multiple Myeloma in the Czech Republic
- PMID: 28903569
- DOI: 10.14735/amko20172S35
Epidemiology of Multiple Myeloma in the Czech Republic
Abstract
Background: Multiple myeloma (MM) is a cancer of plasma cells with an incidence of 4.8 cases per 100,000 population in the Czech Republic in 2014; the burden of MM in the Czech Republic is moderate when compared to other European countries. This work brings the latest information on MM epidemiology in the Czech population.
Material and methods: The Czech National Cancer Registry is the basic source of data for the population-based evaluation of MM epidemiology. This database also makes it possible to assess patient survival and to predict probable short-term as well as long-term trends in the treatment burden of the entire population.
Results: According to the latest Czech National Cancer Registry data, there were 504 new cases of MM and 376 deaths from MM in 2014. Since 2004, there has been a 26.9% increase in MM incidence and an 8.3% increase in MM mortality. In 2014, there were 1,982 persons living with MM or a history of MM, corresponding to a 74.4% increase when compared to MM prevalence in 2004. The 5-year survival of patients treated in the period 2010-2014 was nearly 40%.
Conclusion: The available data make it possible to analyse long-term trends in MM epidemiology and to predict the future treatment burden as well as treatment results.Key words: multiple myeloma - epidemiology - Czech National Cancer Registry - Registry of Monoclonal Gammopathies - Czech Republic.
Similar articles
-
Epidemiology of Plasma Cell Leukemia in the Czech Republic.Klin Onkol. 2019 Winter;32(1):47-51. doi: 10.14735/amko2019. Klin Onkol. 2019. PMID: 30764629 English.
-
Cancer incidence and mortality in the Czech Republic.Klin Onkol. 2014;27(6):406-23. doi: 10.14735/amko2014406. Klin Onkol. 2014. PMID: 25493580
-
Czech Registry of Monoclonal Gammopathies - Technical Solution, Data Collection and Visualisation.Klin Onkol. 2017 Summer;30(Supplementum2):43-50. doi: 10.14735/amko20172S43. Klin Onkol. 2017. PMID: 28903570 English.
-
Plasma Cell Myeloma - 20-Year Comparative Survival and Mortality of Three Plasma Cell Myeloma ICD-O-3 Oncologic Phenotypes by Age, Sex, Race, Stage, Cohort Entry Time-Period and Disease Duration: A Systematic Review of 111,041 Cases for Diagnosis Years 1973-2014: (SEER*Stat 8.3.4).J Insur Med. 2018;47(4):203-211. doi: 10.17849/insm-47-04-1-9.1. Epub 2019 Jan 22. J Insur Med. 2018. PMID: 30668210
-
Epidemiology of gallbladder and bile duct malignancies in the Czech Republic.Cas Lek Cesk. 2019 Spring;158(2):52-56. Cas Lek Cesk. 2019. PMID: 31109163 Review. English.
Cited by
-
Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma.Front Immunol. 2018 Nov 16;9:2431. doi: 10.3389/fimmu.2018.02431. eCollection 2018. Front Immunol. 2018. PMID: 30505301 Free PMC article. Review.
-
Rapid discrimination of multiple myeloma patients by artificial neural networks coupled with mass spectrometry of peripheral blood plasma.Sci Rep. 2019 May 28;9(1):7975. doi: 10.1038/s41598-019-44215-1. Sci Rep. 2019. PMID: 31138828 Free PMC article.
-
Improved Screening of Monoclonal Gammopathy Patients by MALDI-TOF Mass Spectrometry.J Am Soc Mass Spectrom. 2023 Dec 6;34(12):2646-2653. doi: 10.1021/jasms.3c00166. Epub 2023 Nov 23. J Am Soc Mass Spectrom. 2023. PMID: 37994781 Free PMC article.
-
Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal Gammopathies.Blood Cancer J. 2023 Sep 27;13(1):153. doi: 10.1038/s41408-023-00906-7. Blood Cancer J. 2023. PMID: 37752128 Free PMC article.
-
Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas.Biomedicines. 2022 Oct 11;10(10):2535. doi: 10.3390/biomedicines10102535. Biomedicines. 2022. PMID: 36289797 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical